(American Journal of Pathology. 2001;159:803-808.)
© 2001 American Society for Investigative Pathology
Phospholipase C
2 Expression Characterizes the Neoplastic Transformation of the Human Gastric Mucosa
Marco Marchisio*,
Angela Di Baldassarre*,
Domenico Angelucci
,
Elisabetta Caramelli
,
Amelia Cataldi*,
Sergio Castorina
,
Adriano Antonucci*,
Luigina Di Giovannantonio
,
Cosima Schiavone¶,
Rosa Di Biagio*,
Mirella Falconi||,
Giorgio Zauli* and
Sebastiano Miscia*
From the Section of Human Anatomy at the Department of
Biomorphology,*
the Section of Pathology at the Department
of Oncology and Neuroscience,
the Department
of Medicine and Aging Sciences,¶
School of
Medicine, University of Chieti, Chieti; the Institute of Histology and
General Embryology,
University of Bologna,
Bologna; the Institute of Human Anatomy,
University of Catania, Catania; and the Institute of
Cytomorphology,||
Consiglio Nazionale Delle Ricerche,
Bologna, Italy
 |
Abstract
|
|---|
The expression, cellular
distribution, and activity of PIP2-specific
phospholipase C (PLC) in healthy human gastric-mucosa cells have been
recently studied in our laboratories and a direct evidence for an
almost exclusive expression of PLC ß isoforms, with the
exception of PLC ß4, has been provided. These results
addressed our attention to possible modification of PLC expression and
activity during neoplastic transformation of the human gastric mucosa.
In the present article we present results indicating that PLC
2 is
markedly expressed in type II intestinal metaplasia and in the
adenocarcinoma whereas traces of other PLC isoforms were sometime
detected. Interestingly, we found that type I intestinal
metaplasia was in the majority of the cases PLC
2-negative,
but when expressed, this type of metaplasia generally
considered as benignant, always evolved toward neoplastic
transformation. These results therefore readdress the question of
surveillance of the patients with type I intestinal metaplasia and
suggest that PLC
2 expression might be a possible marker of gastric
malignant transformation.
 |
Introduction
|
|---|
The involvement of phospholipase C (PLC) in the mechanisms
regulating the activity of the gastric mucosa cells has been recently
proposed.1,2
Pharmacological trials have indicated that
the modulation of inositol triphosphate production and consequently of
Ca++ mobilization may influence gastric
secretion.3
In addition PLC has also been reported to play
a role in the cytoprotection activated after damaging concentrations of
deoxycholate in human gastric cells.4
Moreover, studies
performed on rabbit antrum have provided important clues toward the
existence in gastric myocytes of hormone-specific receptors coupled to
phosphoinositide signaling pathways.5
Very recently we
have investigated the expression and activity of
PIP2-specific PLC in healthy human gastric-mucosa
cells providing direct evidence for an almost exclusive expression of
the PLC ß family, with the exception of PLC ß4, and at the same
time supplying a cellular cartography of each represented isoform of
this family.6
These results prompted us to investigate
whether the expression and the activity of the PLC isoforms vary during
neoplastic transformation of the human gastric mucosa.
Intestinalization of the gastric mucosa is a widely demonstrated
reaction to external injury that may increase cancer risk at long term,
therefore studies aimed at highlighting
histochemical or cytochemical features implicated with such a risk
would be of help because the identification of premalignant hallmarks
might address early therapeutic strategies. Thus, the goal of this
study was to investigate the expression of the PLC isoforms in the
human metaplastic, dysplastic, and neoplastic gastric mucosa cells.
 |
Materials and Methods
|
|---|
Tissue
Tissues were obtained from gastric biopsies performed in 16
healthy consenting donors and 45 informed patients, 25 of whom were
affected by type I intestinal metaplasia (IM).
Protein Fractionation, Immunoprecipitation, and Western Blotting
Cell homogenates were resuspended in lysis buffer (10 mmol/L
Tris-HCl buffer, pH 7.4, 1% Nonidet P-40, 150 mmol/L NaCl, 1 mg/ml
bovine serum albumin, 1 mmol/L vanadate, 50 mmol/L sodium fluoride) and
left on ice for 30 minutes. Cell lysates (20 µg of protein) were
separated through 8% sodium dodecyl sulfate-polyacrylamide gel
electrophoresis, transferred onto nitrocellulose, and incubated for 1
hour at room temperature with rabbit polyclonal anti-PLC ß1, ß2,
ß3, ß4,
1,
2,
1, and
2 antibodies (
3 and
4 not
yet commercially available) (1:100; Santa Cruz Biotechnology, Santa
Cruz, CA). For anti-PLC immunoprecipitation, cell lysates (400 µg of
proteins) were incubated at 4°C for 60 minutes with anti-PLC ß1,
ß2, ß3, ß4,
1,
2,
1, and
2 antibodies previously
coupled to magnetic beads coated with secondary antibodies.
Immunocomplexes were collected by a magnet and washed several times
with RIPA buffer (phosphate-buffered saline containing 1% Nonidet
P-40, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate) in the
presence of protease inhibitors.
PIP2-Specific PLC Activity Assay
PIP2-specific PLC activity was investigated
using a [3H]-labeled PIP2
exogenous substrate containing equal amounts of dried cold
PIP2 and ]3H[
PIP2 (specific activity, 30,000 dpm/nmol;
Amersham). Briefly, 50 µg of protein from homogenated human gastric
biopsies or, when required, equal amounts of immunocomplexes were
incubated in 3 nmol
[3H]-PIP2 (as exogenous
substrate), 150 mmol/L NaCl, 10 mmol/L 2-(N-morpholino) ethane-sulfonic
acid, 0.06% taurodeoxycholate, and 10 mmol/L
CaCl2 at 37°C for 30 minutes. Inositol lipid
extraction was performed in chloroform/methanol/chloric acid (1:2:0.1).
After two washes in methanol/1 mol/L chloric acid (1:1), the lipid
phase was chromatographed on silica gel plates in
chloroform/methanol/ammonium hydroxide/water (45:35:2:8) and spots,
identified using PIP2 standards, were scraped off
and counted by liquid scintillation.
Immunohistochemical Analysis
Sections were prepared from biopsies performed in the gastric
antrum. Diagnosis of dysplasia or neoplasia were made on the bases of
the 1998 Padova and Sidney International Classifications,
respectively.7,8
Deparaffinized sections were hydrated
into distilled water through a series of graded alcohols (ethanol 100,
95, and 70%). Endogenous peroxidases were inhibited by washing for 15
minutes in distilled
water-H2O2 3%. The slides
were then incubated with rabbit polyclonal IgG anti-PLC: ß1, (G-12),
ß2 (Q-15), ß3 (C-20), ß4 (C-18),
1 (530),
2 (Q-20),
1
(C-19), and
2 (C-19) (Santa Cruz Biotechnology) at the dilution of
1:125 in TBS (10 mmol/L Tris-HCl, pH 8.0; 150 mmol/L NaCl) for 90
minutes at room temperature. TBS was used in negative controls instead
of the primary antibodies. The immunoperoxidase assay was performed
with an ultrastain polyvalent-horseradish peroxidase immunostaining kit
and the antibody localization was detected by the AEC kit (YLEM, Rome,
Italy), according to the manufacturers suggestions. The sections were
washed with water, counterstained with Mayers hemallume for few
minutes, and then rinsed copiously in tap water. Glycerinated gelatin
(Sigma, St. Louis, MO) was used for coverslipping the sections. The
histological diagnosis was blindly performed by three different
observers.
 |
Results
|
|---|
Because previous data obtained from an in vitro
PIP2-specific PLC activity assay performed on
human healthy whole mucosa homogenates indicated an evident involvement
of the phosphoinositide machinery in gastric cell
metabolism,6
we sought to identify which PLC isoforms were
involved in the hydrolytic activity in human neoplastic gastric cells.
Therefore we performed an in vitro assay on gastric cell
extracts after sequential immunoprecipitation of each PLC isozyme by
means of appropriate antibodies. Results indicated that the hydrolytic
activity in the PLC
1/PLC
2 or in the PLC ß family-deprived
extracts was highly comparable to that in total homogenates, whereas in
the PLC ß1/PLC ß2-deprived extracts activity was nearly absent when
compared to whole cell extracts (Table 1)
. The same assay performed with
collected immunoprecipitated PLC
1/PLC
2 isoforms yielded a level
of hydrolytic activity very similar to the one measured in the total
homogenates, whereas very scarce or no activity was noticed in PLC
and in PLC ß immunocomplexes. Further sequential extraction of PLC
1 from PLC
1/PLC
2 immunocomplexes showed that the main
contribution to the PLC activity was accounted for PLC
2 (Table 2)
. The histochemical analysis performed
on the gastric mucosa from patients affected by type II IM dysplasia or
adenocarcinoma revealed a dramatic shift of the PLC isoform expression
when compared to the healthy samples. Indeed, in the human gastric
mucosa undergoing neoplastic transformation only a marked PLC
2
reaction was assessed (Figure 1E)
. The
specificity of the PLC
2 reaction was strongly corroborated by the
finding that in microscopic fields displaying both neoplastic and
normal glands, PLC
2 reaction was clearly assessed only in the
neoplastic cells (Figure 1
; BE), essentially confined to the
cytoplasmic compartment as evidenced by higher microscopic
magnification (Figure 2)
. These results
were confirmed by the Western blot analysis that showed a high recovery
of PLC
2 in neoplastic gastric mucosa when compared to the
expression of the other isoforms (Figure 3)
. Of interest was the finding that the
gastric mucosa affected by type II IM was PLC
2-positive (Figure 1D)
whereas the type I IM was PLC
2-negative (Figure 1C)
with the
exception of eight patients that displayed an evident PLC
2
expression (Table 3
; Figure 1D
). To
assess whether PLC
2 was normally expressed in the human healthy
intestinal mucosa we also looked for this PLC isoform in the duodenum
mucosa and results confirmed that PLC
2 is primarily represented in
the intestinal mucosa (not shown). Of note, PLC
2 was not expressed
in the mucosa affected by inactive gastritis (Figure 4A)
, whereas pictures of dysplastic
gastritis (gastric ulcer) were found positive for PLC
2 (Figure 4B)
.

View larger version (107K):
[in this window]
[in a new window]
|
Figure 2. Magnified section of gastric cancer cells. Location of PLC 2 is
almost totally confined to the cytoplasmic compartment.
|
|

View larger version (71K):
[in this window]
[in a new window]
|
Figure 4. Immunohistochemical analysis of PLC 2 expression in human inactive
gastritis (A)
and in gastric ulcer
(B). The
expression of the enzyme is slightly but clearly detectable only in the
ulcer tissue.
|
|
 |
Discussion
|
|---|
The occurrence of a signal machinery regulated by receptor coupled
via distinct G proteins to different effector enzymes, including
PIP2-specific PLC has already been reported in
gastric structures2-5
and recently we have provided
evidence that the PLC ß is almost exclusively expressed and engaged
in the healthy human gastric mucosa cells.6
The PLC family
includes three types (ß,
, and
) and counts at least 10
isoforms whose expression and activity vary depending on cell type or
tissue.9-11
In this article we report for the first time
to our knowledge, results indicating that the specific expression of
the PLC ß isoforms in the healthy human gastric mucosa is
dramatically replaced by a unique expression of PLC
2 during the
neoplastic transformation. Investigations of histochemical alterations
in the human gastric mucosa, with a view to identifying particular
premalignant patterns provided, to date, conflicting results. The
Padova Classification7
of gastric dysplasia and related
lesions have proposed five broad categories reflecting the degree of
certainty that can be achieved with the histopathological material
available: 1) negative for dysplasia, 2) indefinite for dysplasia, 3)
noninvasive neoplasia, 4) suspicious for invasive carcinoma, and 5)
invasive adenocarcinoma. The first group includes both normal tissue
and IM. Although IM may increase cancer risk at long term, the
metaplastic glands are generally not considered
neoplastic.12
Nevertheless, attention has been paid to
possible features that may have implications concerning gastric cancer
development.13
Two types of IM are conventionally
classified: type I also called "complete IM," which is thought to
need no requirement of surveillance of the patient and type II also
named "incomplete IM," which is generally believed to increase
cancer risk. Our results demonstrate that PLC
2 expression
characterizes the metaplastic and neoplastic evolution of human gastric
mucosa and readdress the question of the surveillance of the patient
affected by type I IM. Indeed in a consistent number of patients (8
over 25) with areas of type I IM PLC
2-positive, the follow-up
revealed in all cases the development of a gastric cancer, whereas type
I IM PLC
2-negative sometime associated to gastric ulcer but thus
far (3 years from the type I IM diagnosis), never to neoplastic
evolution. These findings would indicate PLC
2 as a possible
hallmark predictive of neoplastic transformation in the human gastric
mucosa. In this context, the absence of PLC
2 expression in the
inactive gastritis and the discrete expression of this enzyme in the
gastric ulcer sharply could suggest for PLC
2 a role of possible
indicator of neoplastic evolution. The relationship between PLC
overexpression and neoplasia has been already suggested in different
cell types because PLC
1 has been found overexpressed in human
colorectal cancer14
and familial adenomatous
polyposis15
even though the factors that cause such an
overexpression remain uncovered, whereas PLC ß3 has been implicated
in neuroendocrine gastroenteropancreatic tumors.16
In this
regard a polymerase chain reaction analysis would be of great help in
defining the genetic picture for the complete understanding of the role
of PLC
2 in gastric cancer, but, thus far, sequences of this isoform
are not available. Nevertheless the results here presented highlight
the almost unique involvement of PLC
2 in the neoplastic
transformation of the human gastric mucosa and in this context the
possibility that the expression of this enzyme in type I IMs could
represent a predictive marker of cancer evolution should be taken into
account. The signaling pathway implicated with the PLC
2
overexpression remains obviously to be defined. Certainly the current
challenge is to clarify the nature and dynamics of the membrane-enzyme
microinterface and their relation. In higher plants the
isoforms
are involved in the response to nutritional and environmental stresses,
particularly cyclin-dependent growth control, but the details of what
regulates this PLC are unknown.17
The lack of information
about the physiological meaning of this isoform, addressed our
laboratories to work oriented to design PLC
2 sequence in the
attempt to develop early prognostic support and related therapeutic
strategies.
 |
Footnotes
|
|---|
Address reprint requests to Prof. Sebastiano Miscia, Department of Biomorphology, Via dei Vestini 6, 66100 Chieti, Italy. E-mail:
s.miscia{at}morpho.unich.it
Supported by Italian MURST Confin 99.
Accepted for publication May 23, 2001.
 |
References
|
|---|
-
Kitsukawa Y, Turner RJ, Pradan TK, Jensen RT: Gastric chief cells possess NK1 receptors which mediate pepsinogen secretion and are regulated by agents that increase cAMP and phospholipase C. Biochim Biophys Acta 1996, 13:105-116
-
Takahashi S, Okabe S: Stimulatory effects of sacralfate on secretion and synthesis of mucus by rabbit gastric mucosal cells. Involvement of phospholipase C. Dig Dis Sci 1996, 41:498-504[Medline]
-
Wang L, Gantz I, Del Valle J: Histamine H2 receptor activates adenylate cyclase and PLC via separate GTP-dependent pathways. Am J Physiol 1996, 271:613-620
-
Kokoska ER, Smith GS, Wolff AB, Deshpande Y, Rieckenberg CL, Banan A, Miller TA: Role of calcium in adaptive cytoprotection and cell injury induced by deoxycholate in human gastric cells. Am J Physiol 1998, 275:322-330
-
Rodier G, Magous R, Mochizuki T, le Nguyen D, Bali JP, Bataille D, Jarrousse C: Glicentin and oxyntomodulin modulate both the phosphoinositide and cyclic adenosine monophosphate signalling pathways in gastric myocytes. Endocrinology 1999, 140:22-24[Abstract/Free Full Text]
-
Di Baldassarre A, Marchisio M, Felaco M, Antonucci A, Centurione L, Grilli A, Di Valerio V, Cutroneo G, Schiavone C, Miscia S, Ianetti G: Histochemical and biochemical analysis of phospholipase C isoforms in normal human gastric mucosa cells. Anat Rec 2001, 262:440-444[Medline]
-
Rugge M, Correa P, Dixon MF, Hattori T, Leandro G, Lewin K, Riddel RH, Sipponen P, Watanabe H: Gastric dysplasia. Am J Surg Pathol 2000, 24:166-176
-
Dixon MF, Genta RM, Yardley JH, Correa P, : and the participants in the International Workshop on the Histopathology of Gastritis, Houston 1994: Classification and grading of gastritis. Am J Surg Pathol 1996, 20:1161-1181[Medline]
-
Rhee SG, Bae YS: Regulation of phosphoinositide specific phospholipase C isozymes. J Biol Chem 1997, 272:15046-15048
-
Miscia S, Di Baldassarre A, Cataldi A, Rana R, Di Pietro R, Bosco D, Grilli A, Amerio G, Sabatino G: Immunocytochemical localization of phospholipase C isozymes in cord blood and adult T-lymphocytes. J Histochem Cytochem 1999, 47:929-935[Abstract/Free Full Text]
-
Miscia S, Di Baldassarre A, Sabatino G, Bonvini E, Rana R, Vitale M, Di Valerio V, Manzoli FA: Inefficient phospholipase C activation and reduced Lck expression characterize the signal defect of umbilical cord T lymphocytes. J Immunol 1999, 163:2416-2424[Abstract/Free Full Text]
-
Chen VW, Abu-Elyazeed RR, Zavala DE: Risk factors of precancerous lesions in a high Colombian population. I Salt Nutr Cancer 1990, 13:59-65
-
Rugge M, Leandro G, Farinati F: Gastric epithelial dysplasia. How clinicopathologic background relates to management. Cancer 1995, 76:376-382[Medline]
-
Lee SJ, Lee SD, Park JG, Kim CM, Ryu SH, Suh PG: Overexpression of phospholipase C-gamma-1 in colorectal carcinomas is associated with overexpression of factors that bind its promoter. J Biol Chem 1995, 270:16378-16384[Abstract/Free Full Text]
-
Park JG, Lee YA, Kim SS, Park KJ, Noh DY, Ryn SH, Suh PG: Overexpression of phospholipase C gamma 1 in familial adenomatous polyposis. Cancer Res 1994, 54:2240-2244[Abstract/Free Full Text]
-
Oberg K: Biological aspect of neuroendocrine gastro-enteropancreatic tumors. Digestion 1996, 57:42-44
-
Rebecchi MJ, Pentyala SN: Structure, function, and control of phosphoinositide-specific phospholipase C. Physiol Rev 2000, 80:1291-1335[Abstract/Free Full Text]
This article has been cited by other articles:

|
 |

|
 |
 
V. Bertagnolo, M. Benedusi, F. Brugnoli, P. Lanuti, M. Marchisio, P. Querzoli, and S. Capitani
Phospholipase C-{beta}2 promotes mitosis and migration of human breast cancer-derived cells
Carcinogenesis,
August 1, 2007;
28(8):
1638 - 1645.
[Abstract]
[Full Text]
[PDF]
|
 |
|